Cancer patients in India are encountering treatment interruptions due to a significant nationwide shortage of two key chemotherapy medications, cisplatin and carboplatin. These drugs are widely utilised for treating various cancers such as lung, cervical, ovarian, and head and neck cancers. The scarcity has affected hospitals across the country, comprising both government and private institutions, leading to challenges in securing adequate supplies.

Healthcare providers have expressed concern that the ongoing shortage could adversely impact patient outcomes if the situation persists. Such platinum-based chemotherapy agents are deemed crucial in cancer treatment and form the core of therapeutic strategies aimed at curing the disease. The current supply issues are resulting in delays or modifications to treatment plans, which can severely affect patient care.

Causes Behind the Shortage

The decline in availability of cisplatin and carboplatin has been linked to several factors, including shortages in active pharmaceutical ingredients (APIs), increased manufacturing costs, and disruptions in global supply chains. Industry experts have pointed out geopolitical tensions in West Asia and a substantial surge in platinum prices, which is a primary component in these medications, as significant contributors to the crisis.

Initially, certain hospitals managed to cope by using their existing stockpiles of these drugs. However, dwindling supplies over recent weeks have caused a more serious situation, prompting various patients and their families to seek these medications from multiple pharmacies and healthcare facilities. The scarcity of alternatives to these key drugs makes the current situation particularly concerning.

Medical professionals have had to adapt chemotherapy schedules or alter treatment regimens based on the limited availability of these essential drugs. Dr. MD Ray, a surgical oncologist at AIIMS Delhi, remarked on the disruptive effects that the absence of these medications can have on treatment courses, which may ultimately influence survival and recurrence rates.

Reactions from Health Professionals and Industry

Dr. Shyam Garg, Chairman of Medical Oncology at Sir Ganga Ram Hospital, commented on the gravity of the ongoing situation, noting that their hospital has only one to two days’ worth of supply left. This precarious situation highlights the urgency for solutions to ensure that patients do not have their treatment plans compromised any further.

Furthermore, drug manufacturers have raised alarms regarding escalating production costs. Earlier in 2026, industry associations appealed for a price increase for several platinum-based cancer medications, citing soaring raw material prices that have made manufacturing increasingly unsustainable. The current challenges in the pharmaceutical sector pose a risk not only to patients but to the overall landscape of cancer treatment in India.

The implications of this shortage extend beyond immediate treatment interruptions. If the situation is not rectified in a timely manner, it could lead to broader repercussions for cancer care in the country. Ensuring that essential medications remain accessible is critical in maintaining the continuity of care for those battling this serious illness.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share